Suppr超能文献

在 HIV-乙型肝炎病毒合并感染患者中,乙型肝炎表面抗原(HBsAg)丢失后抗 HBs 抗体的产生。

Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients.

机构信息

INSERM, UMR_S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.

Centre for Immunity, Infection and Evolution, University of Edinburgh, Edinburgh, United Kingdom.

出版信息

J Clin Virol. 2017 Oct;95:55-60. doi: 10.1016/j.jcv.2017.08.008. Epub 2017 Aug 25.

Abstract

BACKGROUND

Hepatitis B surface antigen (HBsAg)-seroconversion, or loss of HBsAg and acquisition of anti-hepatitis B surface (HBs) antibodies, defines functional cure of chronic hepatitis B virus (HBV) infection. After HBsAg-loss, little is known regarding the development of anti-HBs antibodies and even less so in individuals co-infected with HIV.

OBJECTIVES

To determine anti-HBs antibody kinetics after HBsAg-loss and explore determinants of HBsAg-seroconversion in HIV-HBV co-infected patients.

STUDY DESIGN

Patients enrolled in the French HIV-HBV cohort were included if they had >1 study visit after HBsAg-loss. Individual patient kinetics of anti-HBs antibody levels were modeled over time using mixed-effect non-linear regression, whereby maximum specific growth rate and maximal level of antibody production were estimated from a Gompertz growth equation.

RESULTS

Fourteen (4.6%) of 308 co-infected patients followed in the cohort exhibited HBsAg-loss, all of whom were undergoing antiretroviral therapy. Nine (64.3%) of these patients achieved HBsAg-seroconversion during a median 3.0 years (IQR=1.1-5.1) after HBsAg-loss. Across individuals with HBsAg-seroconversion, the fastest rates of antibody growth ranged between 0.57-1.93year (population maximum growth rate=1.02) and antibody production plateaued between 2.09-3.66 log mIU/mL at the end of follow-up (population maximal antibody levels=2.66). Patients with HBsAg-seroconversion had substantial decreases in HBV DNA viral loads (P=0.03) and proportion with elevated ALT levels (P=0.02) and HBeAg-positive serology (P=0.08). No such differences were observed in those without HBsAg-seroconversion.

CONCLUSIONS

Most co-infected patients with HBsAg-seroconversion produced and maintained stable antibody levels, yet kinetics of anti-HBs production were much slower compared to those observed post-vaccination or after clearance of acute HBV-infection.

摘要

背景

乙肝表面抗原(HBsAg)血清转换,即 HBsAg 丢失和抗乙肝表面(HBs)抗体的获得,定义了慢性乙型肝炎病毒(HBV)感染的功能性治愈。HBsAg 丢失后,对于抗 HBs 抗体的发展知之甚少,在 HIV 合并感染的个体中更是如此。

目的

确定 HBsAg 丢失后抗 HBs 抗体的动力学,并探讨 HIV-HBV 合并感染患者 HBsAg 血清转换的决定因素。

研究设计

如果患者在 HBsAg 丢失后有超过 1 次的研究随访,那么将其纳入法国 HIV-HBV 队列研究中。使用混合效应非线性回归模型对患者个体的抗 HBs 抗体水平的时间变化进行建模,通过 Gompertz 生长方程估计最大特异性生长率和最大抗体产生水平。

结果

在队列中随访的 308 例合并感染患者中有 14 例(4.6%)出现 HBsAg 丢失,他们均在接受抗逆转录病毒治疗。在 HBsAg 丢失后中位数 3.0 年(IQR=1.1-5.1)内,其中 9 例(64.3%)患者达到 HBsAg 血清转换。在 HBsAg 血清转换的个体中,抗体生长的最快速度范围在 0.57-1.93 年(人群最大生长率=1.02),在随访结束时抗体产生达到平台期 2.09-3.66 log mIU/mL(人群最大抗体水平=2.66)。与未发生 HBsAg 血清转换的患者相比,HBsAg 血清转换的患者的 HBV DNA 病毒载量有显著下降(P=0.03),且 ALT 水平升高(P=0.02)和 HBeAg 阳性血清学比例(P=0.08)降低。但在未发生 HBsAg 血清转换的患者中并未观察到这些差异。

结论

大多数 HBsAg 血清转换的合并感染患者产生并维持了稳定的抗体水平,但与疫苗接种后或急性 HBV 感染清除后相比,抗 HBs 产生的动力学要慢得多。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验